Shares of Day One Biopharmaceuticals Inc. (DAWN) are soaring 6.30% in pre-market trading on Wednesday, following the release of the company's impressive third-quarter 2025 financial results and a reiterated Buy rating from a prominent analyst.

The biopharmaceutical company, which focuses on developing targeted therapies for genomically defined cancers, reported strong growth in its Q3 earnings release late Tuesday. While specific figures were not provided, the report appears to have exceeded market expectations, fueling investor optimism about the company's financial health and future prospects.

Adding to the positive sentiment, H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Day One Biopharmaceuticals early Wednesday morning. Although the exact price target was not disclosed, this endorsement from a respected financial institution has likely contributed to the stock's pre-market rally. The analyst's continued confidence in DAWN suggests potential upside for the company's shares, further encouraging investors to buy in before the regular trading session begins.